PCM
LGND icon

Prelude Capital Management’s Ligand Pharmaceuticals LGND Stock Holding History

Prelude Capital Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-321
Closed -$15K – 2124
2020
Q1 		$15K Buy
+321
New +$18.2K ﹤0.01% 1049

Other funds holding LGND

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCMLC
Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $5.01B AUM 6.26% 1-Year Est. Return
SDJVC
St. Denis J. Villere & Co New Orleans, Louisiana $907M AUM 10.61% 1-Year Est. Return

Prelude Capital Management's LGND Position: Q3 2020 in Review

Prelude Capital Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2020, closing a stake of 466 shares — an estimated $33K sold.

Prelude Capital Management first reported a position in LGND in Q2 2014 and held it in 10 quarters. The position peaked at $411K in Q2 2014. 252 funds tracked by Wall St. Rank hold LGND as of Q3 2020.

  • Prelude Capital Management reported no remaining Ligand Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Prelude Capital Management sold 466 Ligand Pharmaceuticals shares in Q3 2020, an estimated $33K.
  • Prelude Capital Management first reported a position in Ligand Pharmaceuticals in Q2 2014 and held it in 10 quarters.
  • Prelude Capital Management's Ligand Pharmaceuticals position peaked at $411K in Q2 2014.
  • 252 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2020.

Based on Prelude Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.